United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the company's stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $238.81, for a total value of $859,716.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $31,045.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
United Therapeutics Stock Performance
Shares of UTHR opened at $235.95 on Friday. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The business has a 50-day simple moving average of $233.36 and a two-hundred day simple moving average of $228.79. The stock has a market cap of $11.10 billion, a price-to-earnings ratio of 11.89 and a beta of 0.52. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts' consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to analysts' expectations of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business's quarterly revenue was up 25.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.67 earnings per share. On average, analysts expect that United Therapeutics Co. will post 23.45 EPS for the current year.
Institutional Trading of United Therapeutics
The Gold Grab of the Century
From Colonial Metals | Ad
When central banks buy gold…
The rich buy right along with them.
And central banks are buying at breakneck pace.
Last year… 1,037 tons.
Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.
A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Vanguard Group Inc. grew its position in shares of United Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company's stock worth $1,053,212,000 after purchasing an additional 20,373 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of United Therapeutics by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company's stock worth $123,566,000 after purchasing an additional 9,962 shares in the last quarter. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $100,519,000. LSV Asset Management grew its position in shares of United Therapeutics by 1.0% during the third quarter. LSV Asset Management now owns 383,068 shares of the biotechnology company's stock worth $86,524,000 after purchasing an additional 3,700 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of United Therapeutics by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 319,030 shares of the biotechnology company's stock worth $70,152,000 after purchasing an additional 7,723 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on UTHR shares. Wells Fargo & Company upped their price target on United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a report on Thursday, March 7th. Wedbush reissued an "outperform" rating and issued a $308.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. The Goldman Sachs Group raised United Therapeutics from a "sell" rating to a "neutral" rating and increased their target price for the company from $213.00 to $215.00 in a report on Monday, February 12th. SVB Leerink began coverage on United Therapeutics in a report on Monday, February 5th. They issued an "outperform" rating and a $330.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $294.25.
Read Our Latest Research Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
